Be Greedy on Achillion After Its Selloff NEW YORK (TheStreet) -- The love affair that investors had with biotech company Achillion seems to have run its course, as shares recently plummeted 25% in their biggest one-day loss in six years. It's worth a detailed look at why the stock fell. The company is developing what it calls Sovaprevir, which is also known as ACH-1625. The drug is a once-a-day NS3 protease inhibitor and is currently ...
July 5, 2013 - TheStreet.com